Equivocal role of micelles in Eprex adverse events.
Schellekens
Huub
H
Crommelin
Daan J A
DJ
D001709:Biotechnology / Q000592:standards; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards / Q000639:trends; D016568:Drugs, Generic / Q000009:adverse effects* / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D004921:Erythropoietin / Q000009:adverse effects* / Q000592:standards / Q000627:therapeutic use*; D005062:European Union; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008823:Micelles; D011358:Product Surveillance, Postmarketing / Q000379:methods / Q000592:standards / Q000639:trends; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000209:etiology* / Q000517:prevention & control*
D016568:Drugs, Generic; D008823:Micelles; D011994:Recombinant Proteins; D004921:Erythropoietin